difficile toxins. 48 S.b is a nonpathogenic yeast that represents one of the well-studied probiotics against CDI in both 74 experimental and clinical settings (24, 40) . Randomized double-blind placebo-controlled clinical trials have 75 shown that S.b CNCM I-745 is an effective probiotic in the prophylaxis of antibiotic-associated diarrhea, and 76 the most effective probiotic of prophylaxis against CDI (36, 49) . Studies also indicate that S.b can be used in 77 combination with vancomycin as therapy for relapsing CDI (37, 50) . The putative mechanisms involved in the 78 effectiveness of S.b in CDI include effects directed against the microbiome, the host, as well as C. difficile and 79 its toxins (4, 6, 21, 40, 43) . However, most of the experimental work examining the effects of S.b in CDI 80 models has been limited to non-outbreak-associated C. difficile strains, mostly with strain VPI10463. However, 81 the increased incidence and severity of the CDI global outbreaks has been associated with the emergence of 82 outbreak-associated strains (20) . The exact mechanism of the hypervirulence of these emerging strains is not 83 fully understood (20) . Moreover, studies with the use of probiotics in emerging CDI at both the preclinical and 84 clinical levels have been limited. 85 86 Based on these considerations, we examined the effectiveness of oral S.b administration in preventing 87 morbidity, cecal mucosal histology, and cytokine expression in response to C. difficile infection due to the 88 outbreak-associated strains ribotype 017, 027, and 078 in a well-established model of hamsters. These strains 89 were chosen based on their impact in global outbreaks (51) . Lastly, the effect of the S.b-conditioned medium in 90 cytotoxicity caused by C. difficile filtered supernatants in mouse fibroblasts was also evaluated. 91 92 Materials & Methods: 93 C. difficile culture: 94 C. difficile strains VPI10463 (ATCC stock 43255), ribotype 027 (ATCC BAA-1805), ribotype 078 95 (ATCC BAA-1875), and ribotype 017 (ATCC 43598) were cultured in Difco cooked meat media (#226730 BD, 96 Fisher Scientific, Canoga Park, CA) at 37 o C in anaerobic conditions as previously reported (19) . 97
Hamster model of C. difficile infection: 99 Six weeks old Golden Syrian Hamsters (strain code 049) were purchased from Charles River 00 Laboratories (San Diego, CA) and housed at the UCLA animal facility under standard conditions with a 12 hour 01 light period and a 12 hour dark period per day at 25 o C room temperature. Hamsters were housed in disposable 02 plastic cages with HEPA filtered air circulation, autoclaved bedding, standard animal chow, and sterile water ad 03 libitum. Average body weight of hamsters is 120 g. 04 05
Hamsters (n=5 per group) were orally administered with Clindamycin (30 mg/kg in 200 μL dissolved in 06 water, #C5269, Sigma, St. Louis, MO) on day 1, followed by C. difficile (VPI10463, ribotype 017, 027, and 07 078, 10 3 CFU in 100µL) infection via oral gavage on day 5 as previously described (10). Some hamsters were 08 orally fed with live or heated S.b (3 g/kg body weight in 200 µL dissolved in water) twice a day from day 1 to 09 day 7. The 3g/kg contains 3x10 10 live yeast cells/kg, i.e. ~3.6x10 9 per hamster. A positive control group 10 received vancomycin (50 mg/kg, dissolved in water) orally once a day from day 1 to day 7 while a negative 11 control group received live and heat-treated S.b without C. difficile infection. 12
13
Lyophilized S.b CNCM I-745 powder was provided by Biocodex (Gentilly, France). Lyophilized S.b 14 was dissolved in water to produce live culture for immediate oral administration. Heat-treated S.b was prepared 15 by heating the live culture in a microwave oven for 20 seconds, similar to previously used approaches (2, 9) . 16
The temperature of the heated S.b culture reached 95 o C. Heated S.b cultures were then centrifuged and filtered 117 (0.22μm filter) to generate cell-free supernatants. Heated S.b cell-free supernatants failed to prevent toxin A-118 and B-mediated cell rounding in 3T3-L1 cells. The details of cell rounding experiments are explained in the cell 119 rounding experiments section below. 120 Details of C. difficile infection, vancomycin treatment protocol, and S.b treatment protocol were 122 described in Figure 1A , 2A, and 3A. All animals were euthanized by carbon dioxide gas at day 7. Hamster cecal 123 content, cecal tissue and serum samples were obtained at day 7 for further analysis. Animal experiments were 124 approved by the UCLA Animal Research Committee (protocol 2007-116) . 125
126
Histology scoring: 127
Cecal tissues in H&E staining were used for histology scoring. The severity of enteritis and colitis was 128 graded using three parameters as previously published (41): (i) epithelial tissue damage; (ii) hemorrhagic 129 congestion and mucosal edema; (iii) neutrophil infiltration. A score of 0-3 was assigned to each parameter. 130 Total histology score was determined by the sum of all these three parameter scores (0-9). Four different 131 locations per tissue section were observed. Each tissue section represented results from one hamster. 32
33
Cecal TNFα measurement: 34
The cecal levels of pro-inflammatory hamster TNFα was determined by ELISA kits (MBS2602630,  35 Mybiosource.com, San Diego, CA) according to the manufacturer's instructions. 36
37
Phosphorylated NF-κB immunohistochemistry:
138 Cecal tissues were fixed in 4% paraformaldehyde and embedded in paraffin. After incubation with 139 blocking buffer, sections were incubated with a rabbit polyclonal anti-phosphorylated NF-κB p65 antibody 140 (ab86299, Abcam, Cambridge, United Kingdom, 2 μg/ml dilution) overnight at 4 o C. After washing, sections 141 were incubated with donkey anti-rabbit IgG (19) and slides were stained with an ABC kit for color development 142 (sc-2018, Santa Cruz, Dallas, Texas) . Images were analyzed with a Zeiss AX10 microscope. Histology core 143 facility of the University of California Los Angeles provided assistance in H&E staining and 144 immunohistochemistry experiments. We have verified that the NF-κB signal was specific as the tissue slides 145 7 incubated with secondary antibody but without primary antibody had no detectable signal (data not shown penicillin/streptomycin (10 5 cells/well) in 6-well plates. Cells were grown in 2 ml of medium per well to around 153 70% confluence. Cells were serum starved overnight and then incubated with serum free DMEM media 154 containing S.b-filtered supernatants for 4 hours, followed by toxin A or B (0.1μg/ml) for additional 4 hours. The 55 toxin A was purified from C. difficile VPI10463 as previously described (17, 45) . After 4 hours, 56 microphotographs to observe cell rounding were taken in a blinded manner as we previously described (28). 57
The quantitative difference of cell rounding was observed and scored: 0=normal; 1=mild cell round; 58 2=moderate cell rounding; and 3=severe cell rounding. Four different locations were scored per cell culture 59 wells. 60 61 Some of the cells were treated with cell-free supernatant of C. difficile-conditioned medium instead of 62 toxin A or B. C. difficile (VPI10463, ribotype 017, 027, and 078) was cultured for one week at 37 o C in the 163 anaerobic condition as mentioned above. C. difficile culture suspension was centrifuged at 4000 rpm at 4 o C for 64 15 minutes. The supernatant was transferred to a new tube and then filtered through 0.22 μm filter to remove 65 cells. The cell-free supernatant was added to the 3T3-L1 fibroblast culture (1:10) and further incubated for 4 66 hours. 67
To prepare S.b-filtered supernatants, lyophilized S.b powder was dissolved in DMEM media 69 (100mg/ml, i.e. 10%) overnight in 37 o C with shaking as previously described (6). The culture was then 170 centrifuged at 4000 rpm at 4 o C, followed by a filtration through a 0.22 µm filter to remove the yeast cells. The 171 filtered supernatants were then used to treat the serum-starved cells. The control group was incubated with 172 serum-free DMEM without S.b-filtered supernatant. 173 174 Actin cytoskeleton staining: To detect presence of C. difficile toxin A (tcdA) and toxin B (tcdB) genes in cecal contents, fresh cecal 183 contents were collected into Eppendorf tubes and snapped frozen in dry ice, followed by storage in -80 o C. 200 184 mg of cecal content per hamster was used to prepare bacterial DNA using QIAamp DNA stool Mini kit 185 (#51504, Qiagen, Valencia, CA). The DNA concentration was measured by a Nanodrop machine and was then 186 normalized to 100 ng per PCR reaction with water. The PCR detection of tcdA and tcdB were performed in 187 separate reactions as previously described (34) . All sample reactions were performed in duplicate. After 40 188 cycles of PCR amplification, the Ct values were used to evaluate the presence or absence of tcdA and tcdB 189 genes. High Ct value (~35-40) or absence of Ct value indicates the absence of tcdA and tcdB in cecal content. As shown by a previous report, live S.b is effective in protecting from C. difficile infection in hamsters 202 (5). To establish this model in our laboratory, we administered clindamycin via oral gavage five days before C.
203 difficile inoculation as suggested by a previous report (10). Hamsters were then infected with C. difficile strain 204 VPI10463 as described in Figure 1A . After 48 hours, we collected cecal content, cecal tissues, and serum 205 samples for further analyses. 206 207 We observed that C. difficile-mediated intestinal inflammation was evident primarily in the cecum 08 ( Figure 1B ). Tissue damage was characteristic of mild mucosal erosion/ulceration, severe neutrophil infiltration, 09 and moderate mucosal edema. Images of C. difficile-infected hamsters are shown for evaluation ( Figure 1B) . 10
These quantitative changes were assessed by a histologic score previously used by us (19, 41) . Oral 11 administration of live S.b improved C. difficile-mediated cecal tissue damage as shown by the reduced histology 12 score ( Figure 1B and 1D ), consistent with a previous report (5). However, this improvement was not observed 13 in hamsters fed with the same amount of heated S.b. This finding indicates that the anti-inflammatory effect of 14 S.b was mediated by live S.b only. 15
10
To determine whether S.b alone alters cecal mucosal structure in hamsters, we treated hamsters with live 217 and heated S.b without C. difficile infection. We did not observe any change in cecal tissue histology after live 218 or heated S.b administration for seven days ( Figure 1C -D). 219 220 In the clinical setting, C. difficile infection is commonly treated with antibiotics such as metronidazole, 221 vancomycin, or fidaxomicin (46). Similar to a previous study using a hamster model (27) The incidence and severity of C. difficile outbreaks have been increasing with the emergence of 28 outbreak-associated strains (20) . We next infected hamsters with C. difficile strains ribotype 017, 027, 078, 29 previously associated with several outbreaks (51), using the experimental protocol described in Figure 3A . 30
31
Our results show that ribotype 017-, 027-, and 078-mediated cecal tissue damage was similar to what 32 VPI10463 did with comparable histology scores ( Figure 3B -C). Live, but not heated S.b administration 33 significantly reduced cecal tissue damage and corresponding histology score in hamsters infected with these 34 outbreak-associated C. difficile strains ( Figure 3B pro-inflammatory TNFα protein expression and NF-κB phosphorylation. 238
As shown by our previous report (19) , C. difficile infection results in an increased expression of the pro-239 inflammatory cytokine TNFα in the intestine. In our hamster model, infection with the common C. difficile 240 strain VPI10463 leads to increased cecal TNFα protein expression, compared to cecal tissues without C. difficile infection ( Figure 4A ). Oral vancomycin administration significantly reduced cecal TNFα expression in 242 C. difficile infected hamsters, suggesting successful suppression of C. difficile infection ( Figure 4B ). Live, but 243 not heated S.b, significantly reduced cecal TNFα expression in all C. difficile-infected hamsters by 44 approximately 30% ( Figure 4A and 4C), while live or heated S.b did not affect basal level of cecal TNFα 45 expression in hamsters without C. difficile infection ( Figure 4A ). 46 47 Also, our previous report showed that toxin A mediates TNFα expression via NF-κB activation (19) . 48
Colonic tissues from C. difficile infected mice and ileal tissues of toxin A-treated mice had increased expression 49 of phosphorylated NF-κB (19) . Here we detected NF-κB phosphorylation in hamster cecum using 50 immunohistochemistry. Infection with all C. difficile strains (VPI10463, ribotype 017, 027, and 078) led to a 51 stronger NF-κB phosphorylation in the cecal mucosa than those of uninfected hamsters (shown in brown, 52 Figure 5E ). Quantitative assessment of phosphorylated NF-κB 55 signal was shown in Figure 5F . 56 57 C. difficile toxins A and B cause apoptosis in intestinal tissues (19) . We used TUNEL assay to detect 58 apoptosis in cecal tissues as previously described (19) . Infection of hamsters with all C. difficile strains 59 (VPI10463, ribotype 017, 027, and 078) led to a small number of apoptotic cells in the cecal mucosa as shown 60 by the intense brown spots ( Figure 6A -D). Live or heated S.b did not alter the number of apoptotic cells in the 61 cecal mucosa of C. difficile infected hamsters ( Figure 6A -D). The apoptotic cells in the cecal mucosa of 262 uninfected hamsters were almost undetectable ( Figure 6E ).
263 264 12 We detected whether S.b treatment affects the quantity of C. difficile in the cecum of hamsters using 265 PCR. PCR results indicated the presence of tcdA in cecal contents of hamsters infected with VPI10463, and 266 ribotype 027 and 078 ( Figure 7A ). tcdA was undetectable in ribotype 017-infected hamsters, consistent with the 267 lack of expression of the tcdA in ribotype 017 ( Figure 7A ). tcdB was present in cecal contents of all C. difficile-68 infected hamsters ( Figure 7B ). Live and heated S.b did not affect the quantity of tcdA and tcdB in the cecal 269 content of C. difficile-infected hamsters ( Figure 7A-B ). This finding suggests that the protective effect of S.b 270 does not depend on an antibacterial effect against C. difficile ( Figure 7C) . Toxin A and B disrupt the actin cytoskeleton that leads to cell rounding and then cell death (56) . To 275 better understand the protective mechanism of S.b against toxins produced by C. difficile, we first examined 276 whether cell-free S.b supernatant can prevent toxin A-associated cell rounding. Exposure of 3T3-L1 fibroblasts 77 to purified toxin A for 4 hours resulted in cell rounding ( Figure 8A ). Consistent with a previous study (8), pre-278 treatment of cells with S.b cell-free filtered supernatant (10%) partially prevented the cell rounding effect of 279 toxin A. S.b-filtered supernatants alone without toxin A did not affect cell morphology of 3T3-L1 cells. These 280 results indicate that S.b protects cells against toxin A-mediated cytoskeletal disruption in 3T3-L1 cells. 81
82
On the other hand, toxin B also caused cell rounding in 3T3-L1 cells ( Figure 8B ). Pre-treatment of cells 83 with cell-free S.b filtered supernatant (10%) partially prevented the cell rounding effect of toxin B (Figure 8B) . 284
This finding may provide an explanation for the protective effect of S.b on C. difficile ribotype 017 infection 285 since this strain produces only toxin B (11, 47) . Quantitative assessment of cell rounding is shown in Figure 8C . 286 287 To determine whether S.b protects cells from cell rounding due to outbreak-associated C. difficile, we and then prepared cell-free filtered supernatants. C. difficile supernatants caused cell rounding as observed with 290 purified toxin A ( Figure 9A-D) . Pre-treatment of cells with cell-free filtered S.b supernatant reduced cell 291 rounding caused by C. difficile supernatant ( Figure 9A-D) . Quantitative assessment of cell rounding is shown in 92 Figure 9E . 93 94 The actin cytoskeleton is a known target of toxins A and B (14, 22) . To visualize the distribution of 95 intracellular actin fibers, we stained 3T3-L1 fibroblasts with the ActinGreen reagent. As shown in Figure 10 , 96 toxins A and B disrupted the actin cytoskeleton network in these cells. Addition of S.b supernatants partially 97 inhibited toxin A-and B-mediated actin network disruption, providing a mechanism for the reduction of toxin 98 A-and B-associated cell rounding. 99 00
Discussion: 01
This study demonstrated that prophylactic oral administration of S.b to hamsters significantly prevented 02 cecal tissue damage, TNFα protein expression, and NF-κB phosphorylation caused by three well-established C. 03 difficile outbreak-associated strains. We also show that conditioned media from S.b. CNCM I-745 cultures 04 substantially inhibited cell rounding caused by supernatants from outbreak-associated ribotype 017, 027, and 05 078 C. difficile strains. S.b supernatants also prevented toxin A-and B-mediated cell rounding and actin 06 cytoskeleton network disruption suggesting that this response is, at least in part, responsible for the in vivo 07 protective effect seen in our study. Toxins A and B induce NF-κB phosphorylation that activates TNFα 08 expression (19) . TNFα may also cause cell death (33) and indirectly augments toxin A-mediated cytotoxicity 09 (38) . Thus, the anti-NF-κB in vivo response afforded by S.b. shown here may represent an additional 310 mechanism of action of this probiotic yeast. 311 312
Actin disruption also causes downstream NF-κB activation (30), which is linked to inflammatory 313 cytokine expression. We had demonstrated that NF-κB activation mediates toxin A-induced TNFα expression 314 in monocytes and macrophages (19) . The S.b-mediated protection against toxin-mediated actin disruption may 315 be pivotal in inhibiting cell death and inflammatory responses. S.b conditioned medium also prevented the cell 316 rounding cytotoxic effects of cell-free filtered supernatants from ribotype 017, 027, and 078, suggesting an 317 effect on the cellular effects of C. difficile toxins produced by these strains. Most importantly, however, our 18 results suggest S.b CNCM I-745 administration may be effective in preventing CDI caused by outbreak-19 associated C. difficile strains. 20
21
Multiple additional mechanisms can mediate the S.b. CNCM I-745 effect observed in our study. For 22 example, a previous report demonstrated that S.b increases anti-toxin A IgA secretion in the small intestine (43), 23 suggesting that small intestinal IgA may protect the host from mucosal damage during C. difficile infection. S.b 24 also modifies the human gut microbiome by enhancing short-chain fatty acid-producing bacteria, including 25
Lachnospiraceae and Ruminococcaceae (39). Short chain fatty acids have known anti-inflammatory effects. S.b 26 can also release a protease that digests toxin A and its receptor, thereby inhibiting the toxin effects (3, 4). It is 27 not clear whether S.b can prevent CDI relapse or whether relapse will take place after withdrawal of S.b, but 28 these issues worth further investigation in the future. 29
30
It is quite interesting that S.b had an inhibitory effect against all outbreak-associated C. difficile strains in 31 vivo and in vitro, although the molecular and clinical characteristics of these strains are quite diverse. C. difficile 32 ribotype 017 has been associated with several outbreaks CDI (11, 47) and is characterized by a toxin A negative 33 and toxin B positive genotype (26). According to a mouse study, antibiotic treatment even promotes spore 34 shedding of C. difficile ribotype 017 and subsequent animal-to-animal transmission (31). Since its tissue-damaging effect is thought to be primarily mediated by toxin B (26), the anti-cell rounding activity of S.b in our 336 study indicates its protective effects against toxin B (Figure 8 and 9) . 337
338
Our results also show effective inhibition of C. difficile ribotype 027-induced intestinal inflammation 339 mediated by S.b treatment. C. difficile ribotype 027 is one of the most serious outbreak-associated C. difficile 340 strains responsible for multiple outbreaks in North America, Europe, and beyond (7, 53). It produces both toxin 341 A and toxin B, and an additional toxin, the CDT binary toxin (12) . Although the mechanism of its 342 hypervirulence is not fully elucidated, this strain is fluoroquinolone-resistant (12) and appears to produce more 43 toxin A and toxin B than any other C. difficile strains (35). The binary toxin also possesses cytotoxic activity, 44 but its role in CDI is still not well understood (48). Based on these considerations, the in vivo and in vitro 45 effects of S.b in C. difficile ribotype 027 may be directed against toxin A, toxin B, and/or the binary toxin. 346 Interestingly, another probiotic, Lactobacillus acidophilus GP1B, inhibited C. difficile growth and 347 transcriptional activation of C. difficile toxin-related genes in vitro (57). 348
349
We present here evidence for effective inhibition of C. difficile ribotype 078-associated cecitis mediated 350 by S.b exposure. C. difficile ribotype 078 used to be prevalent among cows and pigs (1). Recent ribotype 078 351 outbreak data showed that it was similar to C. difficile ribotype 027 in severity, but C. difficile ribotype 078 352 tends to affect young people and causes community-associated outbreaks (16). Like C. difficile ribotype 027, 53 ribotype 078 expresses toxin A, toxin B, as well as a binary toxin (44). The effects of S.b against CDI ribotype 54 078 seen in our results can be directed against these toxins. 55
56
Filtered supernatants of S.b cultures exert protective effects against C. difficile toxin A via inhibition of 57 pro-inflammatory chemokine interleukin-8 (IL-8) expression in cultured human NCM460 colonocytes via an 58 ERK-dependent mechanism (6). In a mouse ileal loop model, injection of S.b-filtered supernatants into the 59 loops prevented toxin A-induced tissue damage, ERK activation, and chemokine KC expression (6). This finding is consistent with our results indicating that S.b reduced cecal expression of the pro-inflammatory 361 cytokine TNFα expression in C. difficile-infected hamsters in response to all outbreak-associated strains. 62
63
The overall protective effect of S.b against C. difficile infection in our studies is preventive rather than 64 therapeutic. Once the infection started, S.b was ineffective in suppressing pre-existing intestinal inflammation in 65 hamsters (data not shown). It was necessary to start the S.b treatment before C. difficile infection and continue 66 the treatment post-infection. This suggests that S.b requires some time to be established in the intestine in order 67 to exert its protective effects. In our study, the three outbreak-associated strains are also hypervirulent strains 68 and their enhanced toxicity was associated with a high mortality rate within a short period of time. The typical 69 10% S.b solution regimen in the drinking water used with regular C. difficile strains had no protective effect 70 (data now shown) (52). We used the maximal dose of S.b within its solubility limit (3g/kg, twice per day) to 71 achieve successful inhibition of C. difficile-mediated cecal damage and inflammation. 72
73
In summary, we demonstrated that the preventive effect of S.b against C. difficile in several outbreak-74 associated C. difficile strains was similarly effective. This study is consistent with a recent meta-analysis study 75 that demonstrated a statistically significant efficacy in the prevention of C. difficile diarrhea (15). We suggest 76 -filtered supernatant prevented actin disruption caused by purified toxins A and B 
